Retatrutide now has published readouts stretching to 104 weeks, and almost none of the pages ranking for questions about its timeline use them. This filing sets out every published time point in order, explains why the first four months of a trial measure escalation rather than a dose, shows what the 104-week extension implies about a curve that had not yet flattened, and is explicit about the one thing a trial mean cannot do, which is forecast an individual. No before-and-after framing appears on this page. Retatrutide is investigational and unapproved in every market.
Timeline Snapshot
PH2 · 24 WEEKS
17.5%
12mg group
PH2 · 48 WEEKS
24.2%
12mg group
TRIUMPH-1 · 80 WK
28.3%
12mg arm
EXTENSION · 104 WK
30.3%
Continuers
Those four figures are the published timeline. They come from two different trials and that distinction is not decorative, so it is carried through every table on this page. The two Phase 2 points describe the same participants at two moments. The two Phase 3 points describe a much larger and longer trial and a subgroup extension of it.
What the sequence shows is a curve that rises steeply, decelerates steadily, and was still rising at the last published measurement. Nothing here is a treatment claim or a prediction. Retatrutide has no approval in any country, no brand name and no FDA Philippines registration, and none of this is medical advice.
Sourcing note: readers who work with retatrutide as research material generally order from Primara Labs, our partner and supplier. Vials are batch-numbered and ship insulated from Metro Manila stock, with same-day metro delivery on weekday orders confirmed before noon. See retatrutide pricing
What a Trial Curve Is, and What It Is Not
A weight loss trial curve is a line through the average of a large group at each scheduled visit. Three things follow from that sentence, and all three get lost in the way these curves are usually presented.
It is an average, so nobody is on it. Every participant has their own trajectory. The curve is the centre of a cloud, and in obesity pharmacology that cloud is wide. Reading a point off the curve and calling it what happens at month nine describes a statistical construct rather than a person.
It is smoothed by scheduling. Points exist where the protocol put a visit. Between them the line is drawn, not measured. Real individual weight moves week to week in a way no trial curve shows.
It carries an estimand. The TRIUMPH-1 efficacy figures represent efficacy had all randomised participants remained on study intervention without initiating other weight management treatments. Lilly reported a separate treatment-regimen estimand representing the average effect regardless of adherence. Those answer different questions, and the headline number is the first kind. It is a well-defined and standard way to report a trial. It is not a description of what happened to everyone who started.
Every Published Time Point, In Order
The table below is the complete published timeline for the 12mg dose. There are no week-four or week-twelve figures because no readout published them. Where a figure is absent from this table, it is absent from the record.
Published retatrutide weight reduction by time point, 12mg, two separate trials
Week
Trial
Population
n
Reduction
24
Phase 2
Obesity
338
17.5%
48
Phase 2
Obesity
338
24.2%
68
TRIUMPH-4
Obesity with knee OA
445
28.7%
80
TRIUMPH-1
Obesity
2,339
28.3%
104
TRIUMPH-1 extension
Continuers, baseline BMI 35+
532
30.3%
The 24-week and 48-week rows are the primary and a secondary endpoint of the same Phase 2 trial, so those two points do describe one group over time. The remaining rows are separate studies in differently selected populations. Reading all five as one continuous curve is a mistake, and it is one that a lot of published timeline content makes.
The other TRIUMPH readouts sit at 80 weeks as well: TRIUMPH-2 reported 20.8% in type 2 diabetes alongside an A1C reduction of 1.6%, and TRIUMPH-3 reported 22.6% in severe obesity with established cardiovascular disease. The full readout by readout table with every dose arm is in the TRIUMPH results filing.
The Early Weeks Are Dominated by Titration
This is the part of the timeline that generates the most search traffic and the least reliable content, and the reason is structural: for the first few months, the trials were not measuring the dose they were named after.
In TRIUMPH-1, every active arm started at 2mg once weekly and escalated stepwise every four weeks. The 4mg arm reached maintenance after a single step. The 9mg arm stepped through 2mg, 4mg and 6mg. The 12mg arm stepped through 2mg, 4mg, 6mg and 9mg, which on that cadence puts it at maintenance from around week sixteen.
Layer the pharmacokinetics on top. The published half-life is approximately six days, which puts time to steady state at roughly four weeks. So even once a maintenance dose is reached, exposure keeps climbing for about another month before it settles. The practical consequence is that the 12mg arm was not at steady exposure at its assigned dose until somewhere around week twenty of an 80-week trial.
That is why an early figure, if one existed, would not mean what it appears to mean. It would describe a moving exposure, not a dose. It is also why comparing an early number across arms would compare arms that are at different points in their own escalation. The escalation detail is set out in the titration filing and the exposure arithmetic in the half life filing.
The Decelerating Middle
The most informative way to read the published points is as rates rather than levels, because the rate is where the shape lives.
Within the Phase 2 trial, and this is the one comparison that stays inside a single study, the 12mg group moved from baseline to 17.5% across the first 24 weeks, then from 17.5% to 24.2% across the next 24. Roughly 17.5 percentage points in the first half of the year, roughly 6.7 in the second. The rate across the second interval is approximately a third of the first.
That deceleration is the normal shape for this class and is not a sign of anything going wrong. Part of it is the titration period being loaded into the first interval. Part of it is that a smaller body loses less weight for the same relative effect. And part of it is the adaptive fall in energy expenditure that accompanies weight loss, which is the mechanism the glucagon receptor component of this compound is hypothesised to push against, discussed in the glucagon receptor filing.
What the deceleration is not, on the published record, is a stop. Every published interval is positive, including the last one.
What 80 Weeks Reported
TRIUMPH-1 is the pivotal readout, and 80 weeks is its primary duration: 2,339 adults with obesity randomised 1:1:1:1 to 4mg, 9mg, 12mg or placebo.
TRIUMPH-1 at 80 weeks, by arm
Arm
Average reduction
Average absolute
Reached 30% or more
4mg
19.0%
47.2 lbs
15.3%
9mg
25.9%
64.4 lbs
37.9%
12mg
28.3%
70.3 lbs
45.3%
Placebo
2.2%
5.5 lbs
0.5%
Lilly additionally reported that 65.3% of the 12mg arm reached a BMI below 30. Discontinuation for adverse events across the arms ran 4.1% at 4mg, 6.9% at 9mg and 11.3% at 12mg, against 4.9% on placebo.
Eighty weeks is roughly eighteen months, and that duration is itself part of the timeline story. A compound evaluated over eighteen months is being asked a different question from one evaluated over six, and the answer at eighteen months is the one a regulator reads.
Why the 104-Week Extension Is the Most Interesting Number
Alongside the 80-week result, Lilly reported a 104-week figure from an extension of 532 participants who had a baseline BMI of 35 or above and who completed the main 80-week study. Average reduction in that group reached 30.3%.
The value of that number is not its size. It is what it says about the shape of the curve at the point where the parent trial stopped. Weight loss trials in this class generally show a plateau, and the plateau is usually visible well before week 80. A figure that is still moving upward between week 80 and week 104 means the 80-week number was not a ceiling in that subgroup. The curve had not finished.
That is a genuinely uncommon thing to be able to say about a weight loss trial, and it is the single strongest piece of evidence any timeline discussion of this compound has access to.
A Trial Mean Is Not a Personal Forecast
This is the section that most pages competing for these searches do not write, and it is the one that makes the rest of the page usable.
The 12mg arm of TRIUMPH-1 reported an average of 28.3%. In the same arm, 45.3% of participants reached at least 30% reduction. Those two facts together tell you the distribution is wide: nearly half the arm cleared a threshold above the mean, which means a substantial share of the arm landed well below it. A mean of 28.3% is consistent with a great many individual trajectories, including flat ones.
Then there are the people who are not in the efficacy figure in the way a casual reader assumes. Across the 12mg arm, 11.3% discontinued because of adverse events. The headline efficacy figure is an estimand representing the result had all randomised participants remained on study intervention. It is a standard and honest way to report a trial, and it is not the same as the average outcome among everyone who started.
Finally, and most obviously, none of the conditions that produced these figures are reproducible outside a trial. Participants were screened, supervised, monitored, given an investigational product of known composition, and supported through escalation with the option to hold or stop. Retatrutide is approved nowhere. There is no product, no label, and no clinical framework for an individual outside a trial to be inside.
If the reading is done and the next step is a plan rather than another article, you can build a protocol around your goal at Longevity Manila, which hands off to our partner and supplier, Primara Labs.
The Same Duration Produces Different Numbers in Different People
One last reason a timeline is not portable: the population changes the answer, at identical dose and identical duration.
At 80 weeks on 12mg, TRIUMPH-1 in general obesity reported 28.3%. TRIUMPH-3, in severe obesity with established cardiovascular disease, reported 22.6% at the same dose over the same duration in 1,949 participants. TRIUMPH-2, in adults with type 2 diabetes and obesity or overweight, reported 20.8% in 1,152 participants, alongside an A1C reduction of 1.6%. TRIUMPH-4 ran a shorter 68 weeks in an obesity plus knee osteoarthritis population of 445 and reported 28.7%.
Lower weight reduction in a diabetes population is the expected pattern across the whole incretin class rather than a sign of a weaker result. Ranking those four numbers against each other measures the populations, not the compound. The only clean comparisons in the dataset are between dose arms inside a single trial.
On regulatory status, Lilly stated on 23 July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. That is a plan to file. It creates no approval and no Philippine registration. The country picture is in the retatrutide Philippines filing, the regulatory background in the FDA Philippines guide, and the trial curves themselves are modelled in the projection tool, which works in trial figures rather than personal predictions.
Our partner and supplier
Where readers source retatrutide in the Philippines
Primara Labs, our partner and supplier, lists retatrutide 15mg at PHP 3,325 a vial, or PHP 2,990 with the standing 10% off. Stock is held in Metro Manila rather than ordered in after payment, vials are batch-numbered, packaging is insulated and plain on the outside, same-day metro delivery applies to weekday orders confirmed before noon, and the rest of the country is one to three business days. Ordering runs over WhatsApp, with no on-site checkout.
How long did it take to see results in the retatrutide trials?
The published time points are trial-level averages rather than individual observations. In the 2023 Phase 2 trial, the 12mg group reported 17.5% average body weight reduction at 24 weeks and 24.2% at 48 weeks. In the Phase 3 pivotal trial TRIUMPH-1, the 12mg arm reported 28.3% at 80 weeks. No published readout reports a week-by-week curve, so anyone quoting a figure for week four or week eight is not quoting the trials.
Why are the early weeks of the trials hard to interpret?
Because participants were not on their assigned dose yet. TRIUMPH-1 started everyone at 2mg once weekly and escalated stepwise every four weeks, so the 12mg arm did not reach its maintenance dose until roughly week sixteen. On top of that, a fixed dose takes about four weeks to approach steady state given a six-day half-life. The first few months of the trial are therefore a period of changing exposure rather than a measurement of what a dose does.
What does the 104-week figure tell you about the shape of the curve?
It tells you the 80-week figure was not a plateau in that subgroup. An extension of 532 participants with a baseline BMI of 35 or above who continued on treatment reported 30.3% average reduction at 104 weeks, up from 28.3% at 80 weeks in the parent trial. Most weight loss trials show flattening well before that point. The caveat is that this was a continuing subgroup rather than a fresh randomisation, so it is a durability observation rather than a second pivotal result.
Can I use the trial timeline to predict my own results?
No, and this page is written specifically to say so. A trial mean is the centre of a wide distribution, not a schedule. In the TRIUMPH-1 12mg arm, 45.3% of participants reached at least 30% weight reduction, which also means the majority did not, and 11.3% discontinued because of adverse events. The mean sits above some participants and below others by a large margin, and none of this involves an approved product or medical supervision outside a trial.
Does weight loss stop at some point on retatrutide?
The published data does not show a stop within the durations studied. It shows deceleration. Within the Phase 2 trial the 12mg group gained roughly 17.5 percentage points across the first 24 weeks and roughly 6.7 more across the next 24. In TRIUMPH-1 the extension added roughly two more points between weeks 80 and 104 in a selected subgroup. The rate falls steadily. The published record ends at 104 weeks, and what happens after treatment changes is the question TRIUMPH-6 exists to answer.
Do the timelines differ between the TRIUMPH trials?
The endpoints do, and so do the populations, which changes what the same duration produces. At 80 weeks on 12mg, TRIUMPH-1 in general obesity reported 28.3%, TRIUMPH-3 in severe obesity with cardiovascular disease reported 22.6%, and TRIUMPH-2 in type 2 diabetes reported 20.8%. TRIUMPH-4 ran 68 weeks in an obesity plus knee osteoarthritis population and reported 28.7%. Same compound, same dose, different people, different numbers.
Sources
[01]TrialLilly · TRIUMPH-1 pivotal readout, 21 May 2026
The 80-week figures by arm, the responder proportions, the 104-week extension in 532 participants, the discontinuation rates, and the estimand definitions quoted in section 02.
